See Why MAIA Biotechnology (NYSE: MAIA) Tops Our Pre-Market Watchlist This Morning

*Sponsored Announcing Our Next Potential Breakout Idea For Tuesday! MAIA Biotechnology (NYSE: MAIA) is At The Top Of Our Radar Right Now! MAIA Biotechnology (NYSE: MAIA) Comes Backed By Several Potential Catalysts Including: Analysts Target Up To 640% Upside Potential For (MAIA) With Bullish Calls From Noble Capital And Diamond Equity. With A Market Cap Under $48M, (MAIA)’s Limited Share Structure Has the Potential For Significant Swings If Demand Begins to Shift. FDA Grants THIO Orphan Designations For SCLC, HCC, And Glioblastoma, Highlighting Its Market Potential. Regeneron, A $76B Industry Giant, Expands Its Partnership With MAIA For The THIO-101 Phase 2 Trial. Consider Adding MAIA Biotechnology (NYSE: MAIA) to Your Radar This Week. We Have All Eyes On (MAIA) In The Pre-Market…Consider Taking a Look  While It’s Still Early… February 4, 2025 Dear Reader, Few industries offer the kind of explosive potential seen in biotech, where a single breakthrough can turn an under-the-radar company into a dominant force almost overnight. When a company pushes the boundaries of science with cutting-edge advancements, the market tends to take notice—fast. But some innovations don’t just move the needle—they change the entire game. MAIA Biotechnology (NYSE: MAIA)'s lead asset, THIO, is the only direct telomere-targeting anticancer agent in clinical development. If you’re serious about spotting the next potential biotech breakout idea, MAIA Biotechnology (NYSE: MAIA) needs to be on your radar.  In fact, a few weeks ago, Noble Capital Markets’ Robert LeBoyer slapped a $14.00 target on (MAIA)—which suggests over 640% upside potential from Friday’s $1.89 open. But even before that, Diamond Equity Research set their target at $11.25, pointing to 495% upside potential. While large-cap companies may dominate headlines, small and micro-caps often offer far greater growth potential.  With leaner operations, smaller revenue bases, and the ability to pivot quickly, these companies can scale rapidly when the right catalyst hits. Take MAIA Biotechnology (NYSE: MAIA)—with a market cap under $48M and fewer than 22M shares in the float, this is a company operating with the kind of tight structure that has historically fueled explosive move potential.  And insiders have been loading up…  Since November of 2024, 4 insiders have acquired over 300k shares. When breakthrough science meets a small cap profile like this, the upside potential can be significant. Biotech Showcase™ 2025: (MAIA)’s CEO Highlights THIO’s Progress Dr. Vlad Vitoc unveils the latest on THIO-101’s Phase 2 expansion and what’s next for MAIA in oncology. Dr. Vlad Vitoc, CEO of MAIA Biotechnology (NYSE: MAIA), recently took the stage at Biotech Showcase™ 2025, one of the industry’s most closely watched events. During his presentation, he provided key updates on the THIO-101 Phase 2 trial expansion, which focuses on advanced non-small cell lung cancer (NSCLC) patients receiving third-line (3L) therapy. He also outlined (MAIA)’s plans for upcoming trials targeting multiple high-value cancer indications, highlighting the company’s continued push toward innovative oncology treatments. If you haven’t heard of MAIA Biotechnology (NYSE: MAIA) yet, consider this your wake-up call.  A $34B Market and One Revolutionary Therapy—(MAIA)’s THIO  Takes Center Stage NSCLC remains one of the toughest battles in oncology, but THIO is  stepping up to the fight. MAIA Biotechnology (NYSE: MAIA) lead asset, THIO (6-thio-dG), is the first and only telomere-targeting agent in clinical development.  THIO operates with a dual mechanism of action (MoA): directly targeting telomeres to disrupt cancer cell replication while simultaneously activating an immune response to destroy the cancer cells. The Phase 2 THIO-101 trial focuses on non-small cell lung cancer (NSCLC), a market worth a staggering $34B annually.  Results? Nothing short of groundbreaking.  THIO followed by immune checkpoint inhibitors (ICIs) like Regeneron’s Libtayo® has demonstrated 60% complete response rates in preclinical models.  Patients achieved sustained remission after just two cycles of therapy, with no cancer recurrence—even after rechallenge with 5x the initial cancer cell load.  This isn’t just a treatment—it’s a potential revolution. FDA Recognizes THIO’s Potential Orphan Designations Signal a Major Step Forward for  MAIA Biotechnology (NYSE: MAIA) The race for innovative cancer treatments is relentless, and (MAIA) is chasing a major advancement. NSCLC is the largest cancer market globally, and THIO is positioned to address patients who have become resistant to current checkpoint inhibitors—an enormous unmet need.  The U.S. FDA has already recognized THIO’s promise, granting Orphan Designations for small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and glioblastoma (brain cancer). Let’s talk numbers: NSCLC: $34B annual sales. Checkpoint Inhibitors: $46B global market in 2023, with Keytruda alone generating $9B in NSCLC sales. HCC and SCLC: Combined annual sales of $5B with massive growth potential. MAIA Biotechnology (NYSE: MAIA) owns worldwide rights to THIO, securing the company’s stake in every dollar these markets generate. Breaking the Mold: THIO-101’s Results Speak for Themselves 85% DCR, nearly double median survival—this is more than just a treatment, it’s a breakthrough. The THIO-101 trial has set a new standard for cancer therapies. Patients treated with THIO + Libtayo® showed a disease control rate (DCR) of 85%, far surpassing the 25–35% DCR achieved by traditional chemotherapy.  Even in third-line (3L) settings—where options are typically grim—THIO delivered unprecedented outcomes: Median progression-free survival (PFS): 2.5 months (compared to 1.5 months with chemotherapy). Median overall survival (OS): 5.8 months (nearly double the historical benchmark). Objective response rate (ORR): 38%, a dramatic leap from the 6–10% seen with chemotherapy. These results underscore one thing: THIO is not just effective; it’s transformative. (MAIA)’s Expanding Pipeline Targets Multiple High-Value Cancer Indications (MAIA) isn’t stopping at NSCLC. With a robust pipeline of trials planned for colorectal cancer (CRC), SCLC, HCC, and other solid tumors, the company is poised to address multiple high-value cancer indications.  Interestingly, preclinical models in CRC demonstrated a 100% complete response rate with long-term immune memory formation. The strategy?  Expand THIO’s applications while leveraging collaborations with big pharma players like Regeneron.  MAIA Biotechnology (NYSE: MAIA) Expands Partnership with Regeneron A $76B Industry Leader Backs the Next Phase of THIO’s Clinical Development Around 2 months ago, on December 3, 2024, MAIA Biotechnology (NYSE: MAIA) announced the expansion of its clinical supply agreement with Regeneron, a +$76B industry leader, for the ongoing Phase 2 THIO-101 trial.  This partnership focuses on evaluating (MAIA)'s lead asset, THIO, in combination with Regeneron’s Libtayo® (cemiplimab), an immune checkpoint inhibitor.  The trial targets advanced non-small cell lung cancer (NSCLC) patients resistant to prior checkpoint inhibitor therapies and chemotherapy. Initially signed in 2021, the agreement was designed to supply Libtayo® during the dose selection and safety evaluation stages.  The expanded agreement now supports a broader patient population to assess THIO’s efficacy at the optimal dose. Regeneron provides Libtayo® for all trial patients, while MAIA sponsors the study and retains exclusive global rights to develop and commercialize THIO. This collaboration highlights Regeneron's confidence in THIO’s potential to enhance checkpoint inhibitor outcomes.  With THIO demonstrating promising disease control, progression-free survival, and overall response rates, MAIA Biotechnology (NYSE: MAIA) is advancing its regulatory pathway and exploring the potential for accelerated U.S. approval based on trial results.  Beyond the expansion of THIO-101, the company is systematically building a robust pipeline of Phase 2/3 trials, including THIO-102 (targeting CRC, HCC, and SCLC) and THIO-103 (first-line NSCLC).  Together, these initiatives position MAIA as a biotech powerhouse with a portfolio designed for long-term growth. 70+ Years of Expertise, 5 Patents, and a Cancer Breakthrough (MAIA)’s Leadership Team and Intellectual Property Set the Stage for Disruption (MAIA)’s intellectual property portfolio is as robust as its science. The company holds five issued patents and 29 pending applications covering telomere-targeting compounds and THIO’s immunogenic treatment strategy.  With exclusivity agreements extending to 2041, MAIA is ensuring its technology remains unrivaled for decades. Leadership: Experience That Delivers MAIA Biotechnology (NYSE: MAIA)’s team brings over 70 years of combined experience in oncology and biotech.  CEO Dr. Vlad Vitoc has led the launch of 12 oncology compounds across 20 tumor types, while CSO Dr. Sergei Gryaznov—the co-inventor of THIO—is a global authority on telomeres and cancer.  This isn’t their first rodeo, and it shows. MAIA Biotechnology (NYSE: MAIA) is not just another biotech company. It’s a disruptor, a trailblazer, and quite possibly the future of cancer treatment.  With a pipeline brimming with potential, collaborations with leading industry players, and a market valued in the high ranges, (MAIA) stands out as a company to keep on your radar. In the fight against cancer, (MAIA) is bringing the big guns.  And if their data is anything to go by, this is one company to keep an eye on. 7 Reasons Why MAIA Biotechnology (NYSE: MAIA) is Topping Our Pre-Market Watchlist This Morning… 1. Analyst Coverage:  Noble Capital Markets has pinned a $14.00 target on (MAIA), suggesting 640% upside potential from recent levels, with Diamond Equity Research also setting a bullish target of $11.25. 2. A Game-Changer in Cancer Treatment:  THIO is the only direct telomere-targeting anticancer agent in clinical development, setting it apart in the oncology space. 3. Higher Potential For Growth & Insider Confidence: With a market cap under $48M and fewer than 22M shares in the float, (MAIA) has the kind of structure that could have the potential for significant swings if demand changes. Plus, insiders have acquired over 300K shares since November 2024. 4. FDA Recognition:  The U.S. FDA has granted THIO Orphan Designations for small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and glioblastoma, signaling its potential in high-value markets. 5. Backed by a $76B Industry Leader:  Regeneron, a biotech powerhouse, expanded its clinical supply agreement with (MAIA) for the THIO-101 Phase 2 trial, underscoring confidence in THIO’s ability to enhance checkpoint inhibitors. 6. Breakthrough Clinical Results: The THIO-101 trial has demonstrated an 85% disease control rate and a 38% objective response rate, significantly outperforming traditional late-stage cancer treatments. 7. Serious Expansion Potential: Beyond NSCLC, (MAIA) is advancing multiple Phase 2/3 trials for colorectal, liver, and small cell lung cancer, positioning itself for broader impact across high-value oncology markets. Keeping An Eye On MAIA Biotechnology (NYSE: MAIA) This Week… MAIA Biotechnology (NYSE: MAIA) is making its mark in the biotech space with a groundbreaking approach to cancer treatment and growing industry recognition. Analysts have set ambitious targets, and with its small market cap and limited share structure, any shift in demand could have the potential for significant swings.  THIO’s impressive clinical results, FDA Orphan Designations, and partnership with Regeneron highlight its potential to reshape oncology treatments. With multiple Phase 2/3 trials in progress and expansion into high-value cancer markets, (MAIA) is positioning itself as one to watch closely. We have all eyes on (MAIA) right now—Tuesday’s pre-market. Consider taking a look while it’s still early. We have about 90 minutes before the bell rings. Keep an eye out for my next update—could be coming in a few minutes. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 02/03/2025 and ending on 02/04/2025 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, we have been paid twenty thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid three hundred fifty-four thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither TD Media LLC or its member owns shares of (MAIA:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/maia/#details

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice